Wierzbowski Eversheds Sutherland has advised Biomed-Lublin WSiS S.A. on the sale of rights to the Lakcid, Lakcid Forte, and Lakcid L brands to Polpharma. The net value of the transaction is PLN 17 million.
According to Wierzbowski Eversheds Sutherland, "the buyer has received full registration documentation of these products and also acquired trademark rights and all intellectual property rights associated with them. But this does not mean that the seller, a serum and vaccine manufacturer based in Lublin, Poland, will stop making these products. Biomed-Lublin will continue producing Lakcid and delivering it to Polpharma for at least the next five years."
Polish pharmaceutical firm Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has been operating since 1944. According to Wierzbowski Eversheds Sutherland, "the firm’s main categories of products are (1) medicinal products – prescription drugs, (2) medicinal products – OTC, (3) dietary supplements – preparations for enriching the diet with probiotic bacteria, (4) medical devices and laboratory reagents, and (5) blood products. The company has been listed on the main market of the Warsaw Stock Exchange since January 26, 2015."
The coordinator of the project for Wierzbowski Eversheds Sutherland was Partner Marta Gadomska-Goląb, head of the firm's Consumer Product Compliance & Life Sciences practice. The team also included Counsel Renata Patoka, Partner Pawel Lipski, and Of Counsel Daria Gesicka, as well as Lawyers Blazej Grochowski and Karolina Redlin and Associate Zofia Piekarczyk from the firm's Consumer Product Compliance & Life Sciences practice.
